Takeda Signs US$400 M+ Gene Therapy Pact with Evozyne
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 4 (Table of Contents)
Published: 11 Apr-2022
DOI: 10.3833/pdr.v2022.i4.2683 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Continuing its interest in gene therapies for rare diseases, Takeda has committed up to US$400 M, with an undisclosed double-digit million-dollar upfront payment and research funding payments, to access Evozyne’s protein design platform...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS